Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Tuesday, March 19, 2024 · 697,016,950 Articles · 3+ Million Readers

iXensor announces superior accuracy of its fully digitalized PixoTest® COVID-19 Antigen Test and management solution

PixoTest POCT COVID-19 Antigen Test meets EU standard

Accurate PixoTest POCT COVID-19 Antigen Test

TAIPEI, TAIWAN, May 18, 2021 /EINPresswire.com/ -- iXensor, the pioneer of mobile health, is set to launch its digital COVID-19 rapid antigen test and COVID-19 management solution that digitizes the entire user journey from screening, reporting to access control to combat outbreaks. The clinical performance evaluation has demonstrated superior accuracy of the PixoTest® POCT COVID-19 Antigen Test. The test is currently undergoing the CE self-declaration procedure, and is expected to become available under CE Mark soon using nasal swab or nasopharyngeal swab method.

The PixoTest® POCT COVID-19 Antigen Test is a smart rapid testing solution, which enables fast and cost-efficient screening at decentralized settings. It offers testees the PixoTest Pass app for free self-registration with privacy consent before testing. Then the PixoTest® POCT Analyzer analyzes specimens and transmits test results simultaneously to PixoHealth Pass app users via an encrypted QR code scan. The seamless digital connectivity shortens the wait time for the test report from days to minutes.

With the hand-held size analyzer reading test results objectively, semi-closed communities such as corporations, manufactures, schools and event organizers can minimize the risks of having false-negative cases and sustain a safe environment amidst ongoing pandemic.

A prospective clinical evaluation was conducted in Brazil with symptomatic subjects, the study reported promising accuracy of nasopharyngeal samples — 94% sensitivity and 100% specificity by comparing PixoTest® with RT-PCR assay for the ranges of 0 to 7 days since symptom onset (DSO).

Another two retrospective studies of clinical performance evaluation were completed in the USA, concluding that PixoTest® POCT COVID-19 Antigen Test’s accuracy meets EU standard of quality rapid antigen test. The sensitivity and specificity for nasal specimens are 92.8% and 100% respectively among symptomatic patients.

About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world’s first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical diagnostics across infectious diseases, women’s health, and cardiovascular diseases.

Patrick Liao
iXensor Co., Ltd.
+886 928 570 208
email us here

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release